Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Spero Therapeutics Inc. (SPRO) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Biotechnology
$2.91
+0.01 (0.34%)Did SPRO Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Spero is one of their latest high-conviction picks.
Based on our analysis of 6 Wall Street analysts, SPRO has a neutral consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). Currently trading at $2.91, the median forecast implies a 71.8% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 71.8% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 71.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for SPRO.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 30, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
Dec 20, 2024 | Evercore ISI Group | Josh Schimmer | In-Line | Downgrade | $5.00 |
Dec 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
Nov 18, 2024 | TD Cowen | Ritu Baral | Hold | Downgrade | $0.00 |
Nov 15, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
Oct 3, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
Aug 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
Aug 6, 2024 | TD Cowen | Ritu Baral | Buy | Upgrade | $0.00 |
Aug 6, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
May 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
Apr 4, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
Mar 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
Nov 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
Sep 5, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
Aug 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
Aug 1, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
Jul 20, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
Apr 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
Sep 26, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
The following stocks are similar to Spero based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Spero Therapeutics Inc. has a market capitalization of $162.70M with a P/E ratio of 10.8x. The company generates $44.58M in trailing twelve-month revenue with a -156.5% profit margin.
Revenue growth is -36.6% quarter-over-quarter, while maintaining an operating margin of -247.8% and return on equity of -107.3%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Develops treatments for antibiotic-resistant infections.
Spero Therapeutics generates revenue through the development and commercialization of novel antibiotic therapies aimed at treating multi-drug resistant infections. The company focuses on both oral and intravenous treatment options, leveraging cutting-edge research to create effective alternatives in healthcare.
Headquartered in Cambridge, Massachusetts, Spero Therapeutics addresses the significant public health challenge posed by antibiotic resistance, which is increasingly concerning for global health systems. The companyโs innovative pipeline is crucial for hospitals and healthcare environments where traditional antibiotics are often ineffective.
Healthcare
Biotechnology
32
Ms. Esther P. Rajavelu
United States
2017
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Tebipenem is anticipated to receive approval by mid-2026, with GSK handling commercialization. This could lead to $175 million in milestone payments for Spero over the next year.
Spero's potential $175 million milestone payments and GSK's commercialization support reduce financial risk, enhancing Spero's valuation and attractiveness to investors.
SPRO shares rise following positive phase III results for a GSK-partnered oral drug, advancing towards FDA filing and potential changes in cUTI treatment options.
SPRO's share surge signals strong market confidence following successful drug trials, potentially enhancing revenue and market position in cUTI treatment options.
GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial of tebipenem HBr for complicated urinary tract infections will end early due to efficacy results.
The early efficacy stop of the PIVOT-PO trial for tebipenem HBr suggests strong potential for GSK and Spero, likely boosting their stock prices and market confidence.
Spero Therapeutics and GSK's tebipenem HBr has met primary endpoints in a Phase 3 trial for treating complicated urinary tract infections, with an FDA filing planned for 2H 2025.
Approval of tebipenem HBr could disrupt the cUTI treatment market, addressing a significant healthcare cost burden and enhancing Spero Therapeutics' growth potential and stock value.
Spero Therapeutics, Inc. (Nasdaq: SPRO) reported its Q1 2025 financial results and provided a business update as it continues to develop treatments for rare diseases and MDR infections.
Spero Therapeutics' quarterly results and business update may influence stock performance and investor sentiment, especially regarding its pipeline for rare diseases and MDR infections.
Spero Therapeutics (SPRO) reported a quarterly loss of $0.25 per share, outperforming the Zacks Consensus Estimate of $0.55. This compares to a loss of $0.24 per share last year.
Spero Therapeutics' smaller-than-expected loss signals improved performance, potentially boosting investor confidence and stock value.
Based on our analysis of 6 Wall Street analysts, Spero Therapeutics Inc. (SPRO) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.
According to current analyst ratings, SPRO has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.91. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict SPRO stock could reach $5.00 in the next 12 months. This represents a 71.8% increase from the current price of $2.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
Spero Therapeutics generates revenue through the development and commercialization of novel antibiotic therapies aimed at treating multi-drug resistant infections. The company focuses on both oral and intravenous treatment options, leveraging cutting-edge research to create effective alternatives in healthcare.
The highest price target for SPRO is $5.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 71.8% increase from the current price of $2.91.
The lowest price target for SPRO is $5.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 71.8% increase from the current price of $2.91.
The overall analyst consensus for SPRO is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $5.00.
Stock price projections, including those for Spero Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.